Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric fixed-dose asenapine for acute manic or mixed episodes in bipolar I disorder
2010-022647-38Phase 3
- Sponsor
- Merck & Co.
- Start
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of asenapine in bipolar I disorder (4 arms), sponsored by Merck & Co. Primary endpoint: Change from baseline in Young Mania Rating Scale total score at Day 21.
02
Drugs
asenapine
03
Conditions
bipolar I disorder
Beyond the preview
Go deeper on 2010-022647-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022647-38.